Overview

Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors

Status:
RECRUITING

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of Spirulina-Derived Product for prevention and treatment of oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors.

Phase:

PHASE2

Details

Lead Sponsor:

West China Hospital

Treatments:

Radiotherapy